Why We Recommend Mammograms, and What the 2024 Guidelines Changed

Two sentences show up in our office more than any question about guidelines. The first is "I got a letter saying I have dense breasts, and nobody told me what I am supposed to do with that." The second is "My friend goes every year, my last doctor said every two years, so which one of them is wrong?"

Neither of them is wrong, which is the honest and deeply unsatisfying answer. Screening mammography is one of the few tests in medicine where the major expert bodies read the same trials and land in different places, not because anyone is careless, but because they weigh the costs of screening differently. What follows is what actually changed in 2024, where the disagreement really sits, and the parts of this that patients are almost never told.

The start age moved to 40, and we think that was right

On April 30, 2024, the US Preventive Services Task Force issued a final recommendation that women at average risk begin screening mammography at age 40 and continue every two years through age 74. It carries a B grade, published in JAMA in June 2024. The previous guidance had set 50 as the default start, with screening in your forties framed as an individual choice.

Two things drove the change. Breast cancer incidence has been rising in women in their forties, by about 2% a year, and in the Task Force's own words, starting all women at 40 means "we can save nearly 20 percent more lives from breast cancer overall." The grade matters in a practical way too: under the Affordable Care Act, a USPSTF A or B rating means most private plans cover the screening test without cost sharing, so the recommendation moved the coverage floor along with the clinical advice.

One line in that statement gets misread constantly. For women 75 and older, the Task Force concluded the evidence is insufficient to weigh benefits against harms. Insufficient evidence is not the same instruction as stop. It means the trials did not enroll enough women that age to answer the question, and the decision moves to you, your health, and how many years of benefit a screening test could plausibly buy you.

Everything below assumes average risk. If you have a strong family history, a known pathogenic variant, or chest radiation in your past, the schedule is a different one entirely, and it usually starts with hereditary cancer genetic testing rather than with a mammogram appointment.

Every year or every other year? Why careful doctors disagree

Here is the landscape as it stands in 2026, and it is worth seeing all three side by side:

• USPSTF: every two years, ages 40 to 74.
• American Cancer Society: optional annual screening at 40 to 44, annual at 45 to 54, then a choice between annual and every two years from 55, continuing as long as you are in good health with a life expectancy of at least ten years.
• American College of Radiology: annual screening beginning at 40, and a formal risk assessment for every woman by age 25 to identify who needs more than that.

They are not looking at different data. They are pricing the harms differently. Screening annually means twice as many screening rounds in a decade, which finds some cancers a little earlier and also roughly doubles your exposure to the false alarms, extra imaging, and biopsies that come with them. No randomized trial has ever directly compared annual against biennial screening and shown which one saves more lives, so what you are choosing between is two reasonable readings of an unsettled question.

Dense breasts, 3D imaging, and the letter you now get by law

Since September 10, 2024, every mammography facility in the country has had to tell you your breast density. The FDA amended the Mammography Quality Standards Act in a final rule published on March 10, 2023, and gave facilities eighteen months to comply. Your report now assigns one of four density categories, and your patient summary carries standardized FDA language noting that dense tissue makes cancer harder to see on a mammogram.

This is not a rare finding. Roughly 43% of women aged 40 to 74 have heterogeneously dense or extremely dense breasts. If that letter felt like a diagnosis, it was not one.

Density does two separate things, and conflating them is where the anxiety comes from. First, masking: dense tissue and tumors both appear white on a mammogram, so sensitivity falls. In one large analysis it ran from 87% in women with almost entirely fatty breasts down to 63% in women with extremely dense breasts. Second, independent risk: compared with scattered density, heterogeneously dense tissue carries roughly one and a half times the breast cancer risk, and extremely dense tissue somewhere between one and a half and two times. Real, but modest, and much smaller than a strong family history.

What the letter cannot tell you is whether you need anything beyond a mammogram, because that depends on your whole risk picture rather than one line in a radiology report. For most women with dense breasts the answer is a good 3D mammogram and nothing else. For a smaller group it is supplemental imaging, and we work through who that actually is in our article on who qualifies for a breast MRI.

On 3D versus 2D: tomosynthesis takes multiple low-dose images and reconstructs them into thin slices, so overlapping tissue pulls apart instead of hiding things. Large registry series show it detects more cancers and calls fewer women back. It is now standard at most accredited centers, and if yours offers it, take it. Some facilities still bill it separately, so we check what your plan covers before you commit rather than after.

You got called back. Here is what that usually means

The phone call after a screening mammogram is the part of this that nobody prepares women for, and it is the harm that shows up most often in the data. About 10% of screening rounds generate a callback for additional views or an ultrasound. It is higher after a first-ever mammogram, or when a facility has no prior study to compare against, simply because every benign quirk of your anatomy looks new.

Now the number that should have been in the letter: fewer than 1 in 10 women called back turn out to have cancer. In the national benchmarks it is closer to 6 or 7 in 100, so more than nine out of ten of those calls end in nothing. And if the workup does lead to a biopsy, roughly two out of three of those biopsies come back benign.

None of that makes the waiting pleasant. What reduces the damage is speed and a real explanation, so we book the diagnostic appointment rather than handing you a phone number, and we call you with the result rather than releasing it into a portal at nine at night. Bring your prior images to a new facility, or have them sent, because a comparison film is the single cheapest way to avoid an unnecessary callback.

How this works at Framework Health

1. Risk assessment before the order, not after the result. In your visit we take the family history on both sides, ages at diagnosis, any prior breast biopsy, any chest radiation, and your density from prior reports. The ACR recommends every woman have this done by age 25. Almost nobody has.
2. We order and coordinate, we do not image here. There is no scanner in our office. We send you to an accredited center, ask for tomosynthesis, and make sure prior studies get to the radiologist for comparison.
3. Someone reads the whole report. Not just the flagged line: the density category, the BI-RADS assessment, whether comparison films were available, and whether the recommended interval in the report matches the plan we made with you.
4. Follow-up that actually happens. If you are called back, we get you in within days and explain the result by phone ourselves. If something needs tracking, it gets tracked, the same way we handle colon cancer screening and every other test we order.

Questions we hear about this every week

The bottom line

Start at 40. Pick an interval on purpose rather than by accident, knowing that annual and biennial are both defensible readings of an unsettled question. Read the density letter as information, not as a verdict. And if you get called back, remember that more than nine times out of ten it ends in nothing, which is worth knowing in advance rather than learning afterward. The thing that reliably goes wrong with breast screening is not the choice of interval. It is a result nobody followed up on.